QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$40.60 USD
-1.41 (-3.36%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $40.60 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QDEL 40.60 -1.41(-3.36%)
Will QDEL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for QDEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QDEL
QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down
QuidelOrtho (QDEL) Reports Q2 Loss, Tops Revenue Estimates
QDEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
Strength Seen in National Vision (EYE): Can Its 7.2% Jump Turn into More Strength?
Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report?
Other News for QDEL
CVS stores in some cities run out of COVID tests as cases spike: Bloomberg
Craig-Hallum Gives a Hold Rating to QuidelOrtho (QDEL)
RBC Capital Reaffirms Their Buy Rating on QuidelOrtho (QDEL)
QuidelOrtho Corp (QDEL) Q2 2024 Earnings Call Transcript Highlights: Revenue Meets Expectations ...
QuidelOrtho: Q2 Earnings Snapshot